Adenosine A3 receptor stimulation and cerebral ischemia.

Chronic treatment with the selective adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (IB-MECA) administered prior to either 10 or 20 min forebrain ischemia in gerbils resulted in improved postischemic cerebral blood circulation, survival, and neuronal preservation. Opposite effects, i.e., impaired postischemic blood flow, enhanced mortality, and extensive neuronal destruction in the hippocampus were seen when IB-MECA was given acutely. Neither adenosine A1 nor A2 receptors are involved in these actions. The data indicate that stimulation of adenosine A3 receptors may play an important role in the development of ischemic damage, and that adenosine A3 receptors may offer a new target for therapeutic interventions.
AuthorsD K Von Lubitz, R C Lin, P Popik, M F Carter, K A Jacobson
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 263 Issue 1-2 Pg. 59-67 (Sep 22 1994) ISSN: 0014-2999 [Print] NETHERLANDS
PMID7821362 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Xanthines
  • N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
  • 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine
  • Adenosine
  • Adenosine (analogs & derivatives, pharmacology)
  • Animals
  • Blood Pressure (drug effects)
  • Brain Ischemia (drug therapy)
  • Cerebrovascular Circulation (drug effects)
  • Drug Administration Schedule
  • Female
  • Gerbillinae
  • Neurons (drug effects)
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Xanthines (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: